Endothelin-1 Modulates Angiotensin II in the Development of Hypertension in Fructose-fed Rats

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2009 Jan 14

PMID 19139972

Citations 17

Authors

L T Tran

K M MacLeod

J H McNeill

Affiliations

Soon will be listed here.

Abstract

Two of the most potent vasoconstrictors, endothelin-1 (ET-1) and angiotensin II (Ang II), are upregulated in fructose hypertensive rats. It is unknown whether an interrelationship exists between these peptides that may contribute to the development of fructose-induced hypertension. The objective of this study was to investigate the existence of an interaction between the endothelin and renin angiotensin systems that may play a role in the development of fructose-induced hypertension. High fructose feeding and treatment with either bosentan, a dual endothelin receptor antagonist, or with L-158,809, an angiotensin type 1 receptor antagonist, were initiated simultaneously in male Wistar rats. Systolic blood pressure, fasted plasma parameters, insulin sensitivity, plasma Ang II, and vascular ET-1-immunoreactivity were determined following 6 weeks of high fructose feeding. Rats fed with a high fructose diet exhibited insulin resistance, hyperinsulinemia, hypertriglyceridemia, hypertension, and elevated plasma Ang II. Treatment with either bosentan or L-158,809 significantly attenuated the rise in blood pressure with no effect on insulin levels or insulin sensitivity in fructose-fed rats. Bosentan treatment significantly reduced plasma Ang II levels, while L-158,809 treatment significantly increased vascular ET-1-immunoreactivity in fructose-fed rats. Thus, treatment with the endothelin receptor antagonist prevented the development of fructose-induced hypertension and decreased plasma Ang II levels. These data suggest that ET-1 contributes to the development of fructose-induced hypertension through modulation of Ang II levels.

Citing Articles

Health position paper and redox perspectives - Disease burden by transportation noise.

Sorensen M, Pershagen G, Thacher J, Lanki T, Wicki B, Roosli M Redox Biol. 2023; 69:102995.

PMID: 38142584 PMC: 10788624. DOI: 10.1016/j.redox.2023.102995.

Camel milk protein hydrosylate alleviates hepatic steatosis and hypertension in high fructose-fed rats.

Alshuniaber M, Alshammari G, Eleawa S, Yagoub A, Al-Khalifah A, Alhussain M Pharm Biol. 2022; 60(1):1137-1147.

PMID: 35672152 PMC: 9176680. DOI: 10.1080/13880209.2022.2079678.

The Sweet and Salty Dietary Face of Hypertension and Cardiovascular Disease in Lebanon.

Labban M, Itani M, Maaliki D, Nasreddine L, Itani H Front Physiol. 2022; 12:802132.

PMID: 35153813 PMC: 8835350. DOI: 10.3389/fphys.2021.802132.

Redox Switches in Noise-Induced Cardiovascular and Neuronal Dysregulation.

Frenis K, Kuntic M, Hahad O, Bayo Jimenez M, Oelze M, Daub S Front Mol Biosci. 2021; 8:784910.

PMID: 34869603 PMC: 8637611. DOI: 10.3389/fmolb.2021.784910.

Oxidative stress and inflammation contribute to traffic noise-induced vascular and cerebral dysfunction via uncoupling of nitric oxide synthases.

Daiber A, Kroller-Schon S, Oelze M, Hahad O, Li H, Schulz R Redox Biol. 2020; 34:101506.

PMID: 32371009 PMC: 7327966. DOI: 10.1016/j.redox.2020.101506.

References

Si X, Webb R, RICHEY J . Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats. Can J Physiol Pharmacol. 1999; 77(10):755-62. View

Ezra-Nimni O, Ezra D, Peleg E, Munter K, Rosenthal T . Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat. Am J Hypertens. 2003; 16(4):324-8. DOI: 10.1016/s0895-7061(03)00003-7. View

Ikeda T, Ohta H, Okada M, Kawai N, Nakao R, Siegl P . Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1):S337-41. DOI: 10.1097/00005344-200036051-00098. View

Mortensen L, Fink G . Captopril prevents chronic hypertension produced by infusion of endothelin-1 in rats. Hypertension. 1992; 19(6 Pt 2):676-80. DOI: 10.1161/01.hyp.19.6.676. View

Hwang I, Ho H, Hoffman B, Reaven G . Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987; 10(5):512-6. DOI: 10.1161/01.hyp.10.5.512. View

Rossi G, Sacchetto A, Cesari M, Pessina A . Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999; 43(2):300-7. DOI: 10.1016/s0008-6363(99)00110-8. View

Emori T, Hirata Y, Ohta K, Shichiri M, Marumo F . Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem Biophys Res Commun. 1989; 160(1):93-100. DOI: 10.1016/0006-291x(89)91625-2. View

Nussdorfer G, Rossi G, Belloni A . The role of endothelins in the paracrine control of the secretion and growth of the adrenal cortex. Int Rev Cytol. 1997; 171:267-308. DOI: 10.1016/s0074-7696(08)62590-5. View

Herizi A, Jover B, Bouriquet N, Mimran A . Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension. 1998; 31(1):10-4. DOI: 10.1161/01.hyp.31.1.10. View

10.

Tamura T, Said S, Andersen S, McCune S, Mochizuki S, Gerdes A . Temporal regression of myocyte hypertrophy in hypertensive, heart failure-prone rats treated with an AT1-receptor antagonist. J Card Fail. 2002; 8(1):43-7. DOI: 10.1054/jcaf.2002.32030. View

11.

Gomez-Alamillo C, Juncos L, Cases A, Haas J, Romero J . Interactions between vasoconstrictors and vasodilators in regulating hemodynamics of distinct vascular beds. Hypertension. 2003; 42(4):831-6. DOI: 10.1161/01.HYP.0000088854.04562.DA. View

12.

Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol J . Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis. 2005; 179(1):43-9. DOI: 10.1016/j.atherosclerosis.2004.10.018. View

13.

Jiang J, Tran L, Vasudevan H, Xia Z, Yuen V, McNeill J . Endothelin-1 blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat. Can J Physiol Pharmacol. 2007; 85(3-4):422-9. DOI: 10.1139/y06-088. View

14.

Pollock D . Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension. 2005; 45(4):477-80. DOI: 10.1161/01.HYP.0000158262.11935.d0. View

15.

Reaven G . Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12):1595-607. DOI: 10.2337/diab.37.12.1595. View

16.

Barton M, Carmona R, Ortmann J, Krieger J, Traupe T . Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol. 2003; 35(6):826-37. DOI: 10.1016/s1357-2725(02)00307-2. View

17.

Lariviere R, Moreau C, Rodrigue M, Lebel M . Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. Prostaglandins Leukot Essent Fatty Acids. 2004; 71(2):103-9. DOI: 10.1016/j.plefa.2003.12.021. View

18.

Iyer S, Katovich M . Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens. 1996; 9(7):662-8. DOI: 10.1016/0895-7061(96)00035-0. View

19.

Callera G, Touyz R, Teixeira S, Muscara M, Carvalho M, Fortes Z . ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension. 2003; 42(4):811-7. DOI: 10.1161/01.HYP.0000088363.65943.6C. View

20.

Erlich Y, Rosenthal T . Effect of angiotensin-converting enzyme inhibitors on fructose induced hypertension and hyperinsulinaemia in rats. Clin Exp Pharmacol Physiol Suppl. 1995; 22(1):S347-9. DOI: 10.1111/j.1440-1681.1995.tb02949.x. View